Equibles does not estimate personal net worth.
Get an email with a short summary when Axsome Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get AXSM alertsThe proxy statement of Axsome Therapeutics, Inc. reports total compensation of $3,188,657 for Ari Maizel in fiscal 2025, including a base salary of $530,000. Disclosed compensation is on record for 3 fiscal years. Ari Maizel has spoken on 5 earnings calls across 1 company, most recently for Axsome Therapeutics, Inc. on November 2, 2026. Axsome Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Axsome Therapeutics, Inc. includes Herriot Tabuteau (CEO), Nick Pizzie (CFO), Mark Jacobson (COO) and 4 others.
“I'm pleased to share the progress across our portfolio of three approved medicines, particularly the growing momentum behind AllVelity. Overall, total prescriptions reached approximately 302,000 in the third quarter, an increase of 40% in the third quarter, an increase of 40% in the third quarter.”
“During the second quarter, we saw strong underlying demand growth across our portfolio of three differentiated medicines. In addition, during the quarter, we further strengthened our commercial foundation, positioning us to drive growth across the portfolio over the balance of the year.”
“The first quarter of 2026 was a pivotal period for Axome's brands, reflected in ongoing demand for our medicines, meaningful improvements in payer coverage, and sales force expansion activities.”
“Next topic, Axome delivers strong performance in Q4 and completed 2025 with momentum for Auvelity, Simbravo, and Senozi. Our outstanding medicines continue to meaningfully improve patient outcomes.”
“Q3 represented Axsome's first full quarter with 3 products, and our commercial team advanced efforts across multiple fronts of Axsome's commercial business highlighted by strong performance for AUVELITY, a foundational first full quarter for SYMBRAVO and steady growth for SUNOSI.”
Proxy statement
Start not stated–present
Last confirmed April 24, 2026
Biotechnology · Healthcare
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Axsome Therapeutics, Inc. (AXSM) | M.B.A. Chief Commercial Officer | $530,000 | $3,188,657 |
| 2024 | Axsome Therapeutics, Inc. (AXSM) | M.B.A. Chief Commercial Officer | $510,000 | $3,198,507 |
| 2023 | Axsome Therapeutics, Inc. (AXSM) | M.B.A. Chief Commercial Officer | $445,000 | $3,920,771 |
